Sort publications on year
-
Pharmaco - Epidemiology
Asthma burden according to treatment steps in the French population-based cohort CONSTANCES.
ROCHE N, NADIF R, FABRY-VENDRAND C, PILLOT L, THABUT G, TEISSIER C, BOUEE S, GOLDBERG M, ZINS M.
Respir Med ; 2023;206:107057
-
Biometry and database analysis
Non‑tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study
VEZIRIS N, ANDREJAK C, BOUEE S, EMERY C, OBRADOVIC M, CHIRON R.
BMC Infectious Diseases ; 2021;21(1):1165
-
Pharmaco - Epidemiology
Mepolizumab in a population with severe osinophilic asthma and corticosteroid dependence: results from French early access programme
TAILLE C, CHANEZ P, DEVOUASSOUX G, DIDIER A, PISON C, GARCIA G, CHARRIOT J, BOUEE S, GRUBER A, PRIBIL C, BOURDIN A, HUMBERT M.
Eur Respir J ; 2020;55(6)
-
Biometry and database analysis
The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database
BOURDIN A, FABRY-VENDRAND C, OSTINELLI J, AIT-YAHIA M, DARNAL E, BOUEE S, LAURENDEAU C, BUREAU I, GOURMELEN J, CHOUAID C.
J Allergy Clin Immunol Pract ; 2019;7(5):1477-1487
-
Pharmaco-Economics
Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
HOOGENDOORN M, CORRO RAMOS I, BALDWIN M, LUCIANI L, FABRON C, DETOURNAY B, PMH RUTTEN-VAN MÖLKEN M.
Int J Chron Obstruct Pulmon Dis ; 2019;14:447-456
-
Biometry and database analysis
An attempt at modeling COPD epidemiological trends in France
BURGEL PR, LAURENDEAU C, RAHERISON C, FUHRMAN C, ROCHE N.
Respir Res ; 2018;19(1):130
-
Pharmaco - Epidemiology
Etude de validation de l’échelle BDI/TDI dans la bronchopneumopathie chronique obstructive
LAURENDEAU C, PRIBIL C, PEREZ T, ROCHE N, M-C SIMEONI, DETOURNAY B
Rev Mal Respir ; 26:735-743
-
Pharmaco - Epidemiology
Prévalence de la bronchopneumopathie chronique obstructive (BPCO) : estimation pour la France
BENARD E, DETOURNAY B, NEUKIRCH F, PRIBIL C, EL HASNAOUI A
La Lettre du Pneumologue ; 8(4):158-163
-
Pharmaco - Epidemiology
The SCOPE Study : Healthcare consumption related to patients with Chronic Obstructive Pulmonary Disease in France
DETOURNAY B, PRIBIL C, FOURNIER M, HOUSSET B, HUCHON G, HUAS D, GODARD P, VOINET C, CHANAL I, JOURDANNE C, DURAND-ZALESKI I, the SCOPE Group
Value Health ; 7(2):168-174
-
Pharmaco-Economics
Costs associated with community acquired pneumonia in France
GRECE SABA, LUIZ FLAVIO ANDRADE, JACQUES GAILLAT, PIERRE BONNIN, CHRISTIAN CHIDIAC, HAJNAL-GABRIELA ILLES, HENRI LAURICHESSE, JONATHAN MESSIKA, JEAN-DAMIEN RICARD, BRUNO DETOURNAY, PATRICK PETITPRETZ, GERARD DE POUVOURVILLE
Eur J Health Econom ; 2018;19(4):533-544
-
Pharmaco-Economics
Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011
LAURENDEAU C, CHOUAID C, ROCHE N, TERRIOUX P, GOURMELEN J , DETOURNAY B
Rev Mal Respir ; 2015;32:682-91
-
Pharmaco-Economics
Le coût de l’asthme en France et les implications économiques de son niveau de contôle
GADENNE S, PRIBIL C, CHOUAID C, VERGNENEGRE A, DETOURNAY B
Rev Mal Respir ; 2011;28(4):419-426
-
Pharmaco-Economics
The association between asthma control, health care costs, and quality of life in France and Spain
DOZ M, CHOUAID C, COM-RUELLE L, CALVO E, BROSA M, ROBERT J, DECUYPERE L, PRIBIL C, HUERTA A, DETOURNAY B
BMC Pulm Med ; 2013;22:13-15